What to Expect?
PharmaSynergyRx is known for creating a focused and tailored event that caters to companies pursuing co-development, partnerships, licensing, and commercial deals.
The event always goes beyond the ordinary, offering a comprehensive programme that includes a thoughtfully curated conference agenda, opportunities for informal networking, and structured meetings.
We are working to make your PharmaSynergyRx 2025 event interesting, useful and unique. Take a moment to read about what's in store for you in the next edition.
Clear Product Portfolio Focus
- Primary, Niche, Branded, and Hybrid
- Generics, Value-Added Medicines (VAMs)
- Specialty, Biosimilars, and Hospital Products
- Legacy Products
- New Chemical Entities
- Technology Platforms: Dosage, Formulation, Delivery
1-2-1 Meetings & Networking
Networking and 1-2-1 meetings lie at the very core of our events.
As the event unfolds, you'll find the pre-scheduled time slots and content sessions seamlessly woven into the fabric of the day, ensuring that your agenda is personalised, leaving no room for missed opportunities.
Market Information & Presentations
We aim to provide diverse perspectives and strategic insights. In 2025, the event will feature compelling speakers discussing growth strategies, licensing, BD&L, portfolio approaches, and the evolving regional market landscape.
Partnering Platform
Our partnering platform serves as the launchpad, allowing you to plan and schedule meetings ahead of time. Whether you're seeking that crucial partnership, investment, or collaboration, this digital gateway empowers you to curate a lineup of meaningful interactions.
These are just some of the companies that have confirmed their participation
For the latest list of attendees, please contact yricci@lynx2market.com
2025 Speaker Panel
Strategy and Growth
Daniel Vella Friggieri, Regional CEO – Europe & Middle East, Aspen Healthcare
Navin Thadani, SVP Business Development, Aurobindo Pharma
Rabbur Reza, Chief Operating Officer, Beximco Pharmaceuticals
Thomas Christély, Chief Executive Officer, MetrioPharm
Andrea Castellin, Chief Operating Officer, Brenta
Regulatory Perspectives
Jack Wong, Founder of Asia Regulatory Professionals Association (ARPA), Adjunct Professor, Chinese University of Hong Kong, CEO, RNAscence
Jon de Vlieger, Strategy Director, Lygature
María de la Luz Lara Méndez, Chief Executive Officer, Udelá
Event Sponsors
ApiJect Systems, Corp. is a public-benefit medical technology company that has pioneered a new category of prefilled injection devices with economic, supply chain, and sustainability advantages over traditional offerings. Our mission is to make the safety and performance benefits of prefilled injections affordable and available for most, if not all, injections around the world. The Company’s technology platform is anchored by a well-established manufacturing process called Blow-Fill-Seal (BFS”). BFS is a widely used sterile liquid packaging technology that has been recognized by the FDA as an advanced aseptic process. For more information, visit www.apiject.com
Brenta develops micro and nanotechnology platforms for research and application in the fields of pharmaceutical science and materials. Brenta is therefore active in two business lines: one engaged in nanotechnology and theranostic applications to find solutions that improve the performance of active pharmaceutical ingredients with critical characteristics according to the biopharmaceutical classification system, the other instead focused on the development and production of innovative products with low environmental impact, both at B2B and B2C level.For more information, visit www.brenta.net/en/